Publications by authors named "J L Plantier"
Article Synopsis
- The Central African Republic (CAR) is experiencing a significant HIV epidemic with diverse and unique strains, particularly atypical non-M HIV-1 strains.
- In a study analyzing over 6,000 HIV-positive samples, researchers identified six rare atypical strains, including three HIV-1 group O and three HIV-2 strains, each linked to different years and areas.
- The findings stress that while HIV-1/M remains the most prevalent type in CAR, the presence of rare strains highlights the necessity for updated surveillance and management practices to address the challenges posed by HIV's genetic diversity.
Fourth-generation HIV immunoassays have been developed to reduce the window period of detection during seroconversion period, allowing for the detection of early and established infections. The aim of this work was to evaluate a newly developed assay, Access HIV Ag/Ab combo on the novel high throughput DxI 9000 Access Immunoassay Analyzer (Beckman Coulter, Inc.).
View Article and Find Full Text PDFArticle Synopsis
- The study assessed the performance of the Access anti-HBc Total assay on the DxI 9000 system, involving samples from blood donors and patients to evaluate diagnostic accuracy.
- The assay showed a clinical specificity of 99.58% for blood donors and 99.27% for hospitalized patients, meaning it accurately identified negatives in nearly all cases.
- Additionally, the Access assay demonstrated high sensitivity at 99.78% for positive samples and detected seroconversion earlier than a comparator assay by approximately 1.4 days.
Unlabelled: The susceptibility of genetically divergent HIV-1 strains (HIV-1 non-M) from groups O, N, and P to the CCR5 co-receptor antagonist, maraviroc (MVC), was investigated among a large panel of 45 clinical strains, representative of the viral genetic diversity. The results were compared to the reference strains of HIV-1 group M (HIV-1/M) with known tropism. Among the non-M strains, a wide range of phenotypic susceptibilities to MVC were observed.
View Article and Find Full Text PDFDevelopment and field evaluation in African and Asian countries of an hepatitis B virus PCR on open polyvalent platforms to determine treatment eligibility: results from the "Agence Nationale de Recherche sur le Sida et les hépatites" 12327 study.
Clin Microbiol Infect
August 2024
Objectives: Widespread testing and treatment are essential to eliminate hepatitis B virus (HBV) infection as a public health concern. However, in resource-limited countries, access to HBV PCR is limited. In this study, we developed a quantitative HBV PCR assay on open molecular platforms and evaluate its performance in diagnosing clinically significant HBV DNA thresholds as defined by the WHO (2000 IU/mL, 20 000 IU/mL, and 200 000 IU/mL).
View Article and Find Full Text PDF